Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein

Journal of Pharmacology and Experimental Therapeutics

Volumn 293, Issue 2, 2000, Pages 376-382

  Pauli Magnus, Christiane ^a,b   Von Richter, Oliver ^a   Burk, Oliver ^a   Ziegler, Anja ^a   Mettang, Thomas ^b   Eichelbaum, Michel ^a,c   Fromm, Martin F ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b ROBERT BOSCH HOSPITAL   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO] 2 (4 HYDROXY 3 METHOXYPHENYL) 2 ISOPROPYLVALERONITRILE; CYTOCHROME P450; DEALKYLNORVERAPAMIL; DEALKYLVERAPAMIL; DIGOXIN; DRUG METABOLITE; GLYCOPROTEIN P; INULIN; NORVERAPAMIL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; CELL STRAIN; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CELL LINE; DIGOXIN; EPITHELIAL CELLS; HUMANS; KINETICS; LLC-PK1 CELLS; NITRILES; P-GLYCOPROTEIN; SWINE; VERAPAMIL;

EID: 0034058897     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun 29:880-885.
2. Busse D, Cosme J, Beaune P, Kroemer HK and Eichelbaum M (1995) Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol 353:116-121.
3. Cavet ME, West M and Simmons NL (1996) Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118:1389-1396.
4. Darbar D, Fromm MF, Dell'Orto S, Kim RB, Kroemer HK, Eichelbaum M and Roden DM (1998) Modulation by dietary salt of verapamil disposition in humans. Circulation 98:2702-2708.
5. 14C]verapamil in man. Drug Metab Dispos 7:145-148.
6. Eichelbaum M, Bühl K, Engel G, Ladda E, Schumacher K and Weimer A (1993) Phase I Studie mit R-verapamil zur aufhebung der multidrug-resistenz bei chemotherapie, in Dexverapamil: Circumventor of Multidrug Resistance (Eichelbaum M, Hirth HP, Schumacher K and Traugott U eds) pp 51-56, Kluwer Academic Publishers, Dordrecht, the Netherlands.
7. Fromm MF, Busse D, Kroemer HK and Eichelbaum M (1996) Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 24: 796-801.
8. Fromm MF, Kim RB, Stein CM, Wilkinson GR and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 99:552-557.
9. Gan LS, Moseley MA, Khosla B, Augustijns PF, Bradshaw TP, Hendren RW and Thakker DR (1995) Cytochrome 3A-like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells. Drug Metab Dispos 24:344-349.
10. Gottesman MM and Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
11. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richer O, Zundler J and Kreomer HK (1999) The interaction of digoxin and rifampin: Role of intestinal P-glycoprotein. J Clin Invest 104:147-153.
12. Guengerich FP (1995) Cytochrome P450: Structure, mechanism and biochemistry, in Human Cytochrome Biochemistry (Ortiz de Montanella PR ed) pp 473-535, Plenum Press, New York.
13. Häußermann K, Benz B, Gekeler V, Schumacher K and Eichelbaum M (1991) Effects of verapamil enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in human lymphoma cell lines. Eur J Clin Pharmacol 40:53-59.
14. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418.
15. Hidalgo IJ, Raub TJ and Borchardt RT (1989) Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749.
16. Hunter J, Jepson MA, Tsuruo T, Simmons NL and Hirst BH (1993) Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells: Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 268:14991-14997.
17. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM and Wilkinson GR (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
18. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ and Wilkinson GR (1999) Interrelationship between substrates and inhibitors of human cytochrome 3A and P-glycoprotein Pharm Res 16:408-414.
19. Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR and Eichelbaum M (1993) Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedeberg's Arch Pharmacol 348:332-337.
20. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DK, van Asperen J, Borst P and Schinkel AH (1996) Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119:1038-1044.
21. Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U and Kroemer HK (1990) Interaction of verapamil and cimetidine: Stereochemical aspects of drug metabolism, drug disposition and drug action. J Pharmacol Exp Ther 253:1042-1048.
22. Saitoh H and Aungst BJ (1995) Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine. Pharm Res 12:1304-1310.
23. Sandström R, Karlsson A and Lennernäs H (1998) The absence of stereoselective P-glycoprotein-mediated transport of R/S-verapamil across the rat jejunum. J Pharm Pharmacol 50:729-735.
24. Sandström R and Lennernäs H (1999) Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. Drug Metab Dispos 27:951-955.
25. Schinkel AH, Wagenaar E, van Deemter L, Mol CA and Borst P (1995) Absence of the mdrla P-gLycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96:1698-1705.
26. Schumaeher K, Ladda E, Bühl K, Weimer A, Eser C, Traugott U, Roller E, Löffler B and Eichelbaum M (1993) Reversal of multidrug resistance by R-verapamil, in Dexverapamil: Circumventor of Multidrug Resistance (Eichelbaum M, Hirth HP, Schumacher K and Traugott U eds) pp 57-64, Kluwer Academic Publishers, Dordrecht, the Netherlands.
27. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251:252-261.
28. Shapiro AB, Fox K, Lam P and Ling V (1999) Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone: Evidence for a third drug-binding site. Eur J Biochem 269:841-850.
29. Terao T, Hisanaga E, Sai Y, Tamai I and Tsuji A (1996) Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 48:1083-1089.
30. Tsuruo T, Iida H, Yamashiro M, Tsukagoshi S and Sakurai Y (1982) Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31:3138-3140.
31. 7]verapamil and metabolites in biological fluids by liquid chromatography-mass spectrometry. J Chromat B, in press.
32. von Richter O, Greiner B, Omari T, Dent J, Somogyi A and Eichelbaum M (1999) Metabolism and transport of drugs in the human intestine studied with a perfusion catheter (Abstract). Clin Pharm Ther 65:2.
33. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Del Rev 27:161-170.